This differential sensitivity between wild-type and mutant receptors, combined with the increased dependency of tumor cells on EGFR signaling, provides the wide therapeutic window that makes EGFR inhibitor therapy much more effective in patients with classical activating EGFR mutations. The gene discussed is EGFR; the disease is neoplasm.